Updated: Sanofi's $1.5B pact with Teva in IBD adds fuel to anti-TL1A race against Merck, Roivant and Pfizer
Sanofi wasn’t the only party interested in Teva’s anti-TL1A antibody, but it emerged as the “perfect partner” to secure a deal worth up to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
